默克

Merck hit by sharp decline in HPV vaccine sales in China

US drugmaker reports 17% fall in net income to $4.4bn in the second quarter

Plunging sales of Merck’s blockbuster HPV vaccine in China have caused a sharp fall in the US pharma group’s earnings.

In results published on Tuesday, Merck reported that after the effect of currency fluctuations were stripped out, net income fell to $4.4bn in the second quarter, a 17 per cent decline on the same period a year ago.

Merck has previously warned about the Gardasil vaccines sales slump, saying in February that it was halting shipments to China to help a key local supplier reduce excess inventory.

您已阅读40%(513字),剩余60%(785字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×